The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...

The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain ...

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.